Group items matching

in title, tags, annotations or url

Three leading pharmacists - professor Mahendra Patel, Asif Aziz and Ade Williams - have been recognised in Queen Elizabeth's annual New Year's honours list. Professor Patel, an academic pharmacist from West Yorkshire, was awarded an OBE for his "services to pharmacy." He told Pharmacy Business: "I am truly honoured and deeply humbled by this highly prestigious award that I have always believed was more deserving for others. "That's not to say I'm not proud of it - far from it, although for me it's not necessarily about rewards and recognition but more the intricacies of the journey I embark on and the learning and joy that those encounters bring with it. Most recently, Professor Patel - who has had a broad ranging portfolio career spanning community pharmacy, health education and health promotion, academia, and research - has been involved in promoting clinical trials across community pharmacies in the UK. His latest work has seen him act as one of the national leads for the PRINCIPLE and PANORAMIC trials, run by Oxford University - both trials seek to pioneer repurposed and new drug treatments in the community to prevent hospitalisation due to Covid-19.

The National Institute for Health and Care Excellence (NICE) has rejected the use of olaparib on the NHS for treatment of adults with hormone-relapsed prostate cancer with BRCA1 or BRCA2 mutations which has spread to other parts of the body. In a draft guidance issued today (January 5) NICE said evidence around the drug made by AstraZeneca was uncertain and approving it would not be a good use of NHS funds. Current treatment for metastatic prostate cancer that no longer responds to hormone therapy is chemotherapy with docetaxel, cabazitaxel, or radium 223 dichloride - a treatment option for people with symptomatic bone metastases who have already had docetaxel or cannot have it. NICE said: "Clinical trial evidence showed that people taking olaparib have more time before their disease gets worse, and live longer overall, than people having retreatment with abiraterone or enzalutamide. However, retreatment with abiraterone or enzalutamide is not considered effective and is not standard care in the NHS.

Ahead of World AIDS Day this Wednesday, the Royal Pharmaceutical Society has urged the government to widen access to pre-exposure prophylaxis (PrEP) by making it available through community pharmacies. It argues that such a move could drive down rates of HIV infection across Great Britain. Currently, the medicine - which offers almost total protection from HIV when taken as recommended prior to sex or injecting drugs - is available free of charge only through sexual health clinics. Calling on the government to engage with community pharmacies to improve public health, RPS president Claire Anderson said: "There is a clear opportunity to drive down rates of HIV infection by expanding provision of pre-exposure prophylaxis (PrEP) to community pharmacies and GP practices as part of the government's HIV Action Plan.

Community Pharmacy Wales and the Welsh government have entered an agreement on Thursday (December 16), enabling all pharmacies to deliver provision of contraception, treatment for common minor ailments, and access to repeat medicines in an emergency. Expansion of clinical community pharmacy service will be supported with an increased funding of £20 million a year by April 2024 from the current level of £11.4m. The two bodies have been negotiating the terms of agreement, which also includes plans to roll out a Wales-wide pharmacy prescribing service, allowing trained pharmacists to treat an extended range of conditions that currently require GP visits. The agreement will allow patients to access NHS services closer to home which in turn would free up GP and other NHS services for patients with more complex needs. Eluned Morgan MS, minister for Health and Social Services said: "I welcome the positive approach to negotiations taken by Community Pharmacy Wales, embracing our ambition for a reimagined community pharmacy service, which is an integral part of a strong primary care landscape."

Global demand for Pfizer's oral Covid-19 antiviral treatment Paxlovid has been unexpectedly low due to complicated eligibility requirements, reduced testing, and potential for drug interactions, according to a media report. Demand also has been hampered by the perception that Omicron infections are not that severe. Paxlovid was expected to be a major tool in the fight against Covid after it reduced hospitalizations or deaths in high-risk patients by around 90 per cent in a clinical trial. Thousands of people still die from Covid-19 every week, even as global infections are far off their peak. And there are only a few proven antiviral treatments, of which Paxlovid is the most attractive. The others are Merck & Co's far less effective rival pill molnupiravir, and Gilead Sciences' intravenous remdesivir.

A diet supplemented with vitamin D can help support healthy weight loss and reduce fat percentage, a new clinical study revealed. A trial was conducted over a three-month period with 125 overweight and obese Southeastern European Caucasians with vitamin D deficiency or insufficiency. Participants were prescribed vitamin D3 3000 IU/d oral spray supplementation, or a placebo, alongside a calorie-restricted diet programme of 600 kcal less than the total energy expenditure of each individual. The report stated that the group who were prescribed vitamin D witnessed significant improvements in serum 25(OH)D level and a greater reduction in body weight, BMI, and fat percentage in all individuals within this group. The study supported by BetterYou found that with the prevalence of low vitamin D becoming a serious global health problem in all ages, even in areas with natural sun exposure throughout the year, the study shines a light on the importance of vitamin D supplementation.

NHS cancer check has set a new record, despite pressures on hospitals due to Covid-19, the number of people being treated for the cancer remained higher than before the pandemic, revealed NHS. Over the last 12 months almost three million people were referred for cancer checks which is up by over a tenth on the 2.4 million people referred before the pandemic. "Even at the peak of the Omicron wave, referrals for suspected cancer were at 116 per cent of pre-pandemic levels with around 11,000 people getting checked every day over the last year," said NHS. In order to meet increasing demand for cancer checks, NHS services across the country are expanding their diagnostic capabilities through one stop shops for tests, mobile clinics and cancer symptom hotlines, ensuring people are diagnosed and treated as early as possible to give them a much better chance of beating the disease. More than 30,000 people every month are being invited for lung cancer checks through NHS mobile trucks visiting at risk communities across the country, as part of the biggest programme to improve early lung cancer diagnosis in health service history.

Out of the 2,805 students who sat for the common registration assessment test for pharmacists this June, approximately 2,150 have passed the exam, according to the General Pharmaceutical Council. It assesses pharmacy graduates' knowledge and skills to ensure safe and effective practice as pharmacists. This year, the pass rate was 77 per cent, slightly lower than the 80 per cent pass rate in June 2022, where 2,147 out of 2,697 candidates cleared the assessment, GPhC data showed. The exam comprises a written assessment testing pharmaceutical science and pharmacy practice knowledge and a practical assessment evaluating clinical skills and patient-facing competencies. Eligible candidates must complete an accredited pharmacy degree program and meet GPhC requirements. The assessment is conducted jointly by the General Pharmaceutical Council and the Pharmaceutical Society of Northern Ireland. "The assessment is a primary method for testing trainees' ability to apply knowledge and make professional judgments in pharmacy practice," said Mark Voce, Director of Education and Standards, GPhC. "This is crucial in assuring patients and the public that they are in safe hands."

The Health and Social Care Committee (HSCC) has undertaken an inquiry into prevention and has published its first report of the series which focuses on vaccination. It has announced ten workstreams that will form the basis of inquiry, of which vaccination is one. HSCC said: "The UK has long been one of the world leaders on vaccination - one of the most successful and cost-effective preventative tools available. However, if challenges around uptake and bureaucratic processes in clinical trial set-up are not addressed, there is a very real risk that the UK's position as a global leader could be lost. This cannot be allowed to happen and in this report we set out some of the steps that we think will make a difference." It recommended a more flexible delivery model making use of a wider range of healthcare professionals. "The NHSE vaccination and immunisation strategy must have a strong focus on tackling practical challenges that limit vaccination access, make best use of a wider array of professionals, empower local leaders to pursue ways of addressing uptake in their own areas, and to set out guidance and examples of best practice around how voices other than NHSE can communicate important messaging around vaccination programmes," it suggested.

The National Pharmacy Association has published a medium-term prospectus for the development of pharmacy services, calling it a challenge to old ways of thinking and an opportunity to redefine the sector's role in the NHS. It follows months of dialogue with NPA members about what a clinical future could look like for the sector. The document - Making Changes Meeting Needs - will be shared with the King's Fund and Nuffield Trust who are currently working on a new vision for the future on behalf of Community Pharmacy England. NPA chair, Nick Kaye, said: "Building out from the existing portfolio of services, there are some major opportunities within this decade, encompassing prevention, medicines optimisation, long term medical conditions and urgent care.

The National Pharmacy Association has announced the theme for this year's 'Ask Your Pharmacist Week' campaign - 'Meet Your Local Pharmacy Team'. The campaign, scheduled for October 30 to November 6, seeks to enhance awareness of pharmacy services and initiate dialogues with local stakeholders, highlighting the role and advantages of community pharmacy, the NPA said in a statement. NPA has organised an array of promotional activities, spanning window displays, social media engagements, partnerships with patient groups, radio and TV interviews, and visits to pharmacies by local dignitaries and politicians during the week. "AYP Week 2023 will acquaint individuals with the pharmacist's skill set and the broader community pharmacy workforce, showcasing their collaborative efforts in delivering a secure and efficient service, encompassing NHS clinical care," said Stephen Fishwick, NPA's Head of Communications. "As always, the NPA will furnish campaign resources for our members and other participants interested in engaging with this enduring initiative."

The NHS England has introduced a training programme for 1000 staff to broaden their community pharmacy roles, thereby improving patient access to services. Among them, 500 pharmacy staff will be trained to supervise pharmacists during prescription training, while the remaining 500 will provide support for various training, including pre and post-registration programmes for pharmacists and pharmacy technicians. According to the NHSE, pharmacist and pharmacy technician roles are rapidly evolving due to healthcare changes and increased demand for clinical services in community pharmacy. "There are 3,000 independent prescribing training spots available for 2023/24. Educational supervision is a crucial part of this to enable the ongoing transformation and skills development of the growing pharmacy workforce." The NHSE-funded training, scheduled to begin next month, will ensure that those involved in educational supervision, including Designated Supervisors (DSs), Pre-registration Trainee Pharmacy Technician education supervisors and Designated Prescribing Practitioners (DPPs), can effectively support learners.

The National Health Service will begin its autumn Covid vaccine program next week, a month earlier than planned in response to the spread of a new variant dubbed Pirola. Covid vaccines will be administered to care home residents and housebound individuals from Monday onwards, while over-65s and other vulnerable groups will receive their appointments the week after. On Aug. 30, NHS England shifted the autumn vaccination drive to start on September 11 in response to the new Covid-19 variant, BA.2.86, detected on August 18. The primary groups can book through a national system upon receiving an invitation from the NHS. Some people may get an earlier call from their GP, and a few have already scheduled Covid vaccinations alongside their flu jabs. The NHS will begin inviting other eligible groups from Sept. 18. However, it is important to note that not everyone will receive a call at the same time. These groups will include individuals aged 65 and over, those aged six months to 64 years in a clinical risk category, frontline health and social care workers, and individuals aged 12 to 64 who are carers or household contacts of those with immunosuppression.

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

The Royal Pharmaceutical Society (RPS) is refreshing its Professional Standards for Homecare Services and will be shared for consultation in August to allow comment and input on the updated content. The final version is expected to be completed in the autumn. The standards were originally published in 2013 and are a framework to support teams providing and commissioning homecare services. Homecare medicines services deliver medication, and any necessary associated care, direct to the patient's home with their consent. The standards help patients experience a consistent quality of homecare services, irrespective of provider, will protect them from avoidable incidents and help them get the best outcomes from their medicines. Jennifer Allen, The Chief Pharmaceutical Officer's Clinical Fellow leading the refresh at RPS said: "It has been 10 years since the first set of Homecare Standards were published, so it is important that they are reviewed and brought up to date to reflect current service design, medicine pathways and delivery models to ensure patients receive safe and effective medication supply and associated care."

The government has earmarked £200 million to enhance NHS resilience and expedite patient care during the upcoming winter season. This extra amount will bolster the health service during its busiest period, while protecting elective care so we can keep cutting waiting lists, Prime Minister Rishi Sunak has said. On August 13, the Prime Minister and Health and Social Care Secretary met with clinical leaders and NHS Chiefs to strategise and refine planning for urgent and emergency care, while prioritising the preservation of waiting list targets for the upcoming winter season. "Patients can be reassured that I will always back the NHS, so that those who most need help and support will get the care they need," Sunak said. "Winter is the most challenging time for the health service, which is why we've been planning for it all year - with huge government investment to fund new ambulances, beds and virtual wards." "This £200 million investment, assured by the Department of Health and Social Care as new and additional funding, should aid NHS leaders in their preparations and mitigation for what will be a seriously difficult winter period," said Matthew Taylor, Chief Executive of NHS Confederation. "The priority now is swift allocation of funding to local systems for optimal utilisation."

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and recycling initiative. NHS Trusts and community pharmacies participating in the new scheme will have specialised recycling containers for inhalers installed to simplify public participation, Grundon said in a statement. Inhalers alone contribute to 4 per cent of NHS CO2 emissions, with around 73 million dispensed annually. By 2026, the health service aims to achieve a 50 per cent reduction in carbon emissions from waste management, a target that rises to 80 percent between 2028 and 2032, as outlined in the NHS Clinical Waste Strategy. "This scheme holds the potential to revolutionise the approach of NHS Trusts towards achieving heightened carbon savings and ultimately, net zero emissions," said Chris Edwards, Grundon's General Manager - Technical. "Each discarded pressurised Metered Dose Inhaler (pMDI) contains highly polluting hydrofluorocarbon (HFC) gases - a category of greenhouse gas known to be over a thousand times more detrimental than carbon dioxide in driving climate change." "This initiative securely captures these gases and repurposes them for application in the refrigeration sector. By also recycling the plastic and aluminium components of the device, we are making a noteworthy contribution to the circular economy," he added. Once collected, these will undergo processing at Grundon's specialist recycling facility in Ewelme, Oxfordshire, which is capable of handling more than 200,000 inhalers a day. The company aims to recycle 80 per cent of all prescribed inhalers by 2025, the statement added.

Three pharmacy bodies have called on the government to allow pharmacy students access to the NHS learning support fund (LSF) currently available to students from other healthcare professions. Calling it "unjust", the Royal Pharmaceutical Society (RPS), British Pharmaceutical Students' Association (BPSA), and Pharmacy Schools Council (PSC) have voiced their disappointment over continual exclusion of pharmacy students on clinical placements and asked that pharmacy students are given equal access to the LSF. The Department of Health and Social Care recently announced a 50 percent increase in travel and accommodation allowances for students in nursing, midwifery, allied health professions, medical, and dental courses. However, this initiative notably excluded pharmacy students.

Six pharmacists based in Scotland were acknowledged by the profession this week during a celebratory event held at the home of Scottish pharmacy, the RPS building on Melville Street, Edinburgh. Four pharmacists have been officially conferred with Fellowships of RPS for their significant contributions to the practice of pharmacy. The recipients are: Richard Lowrie Lynn Morrison Deborah Steven Audrey Thompson Two pharmacists, Katherine Davidson and Emily Kennedy, have attained accreditation as consultant pharmacists. This designation is granted in recognition of their demonstrated expertise at a senior level, spanning clinical practice, leadership, research, and education, RPS said in a statement.

The lessons from Covid crisis applied in the future through collaboration can create a better integration between GP practices, hospitals and community pharmacies, Pharmacists Defence Association (PDA) has proposed. Stating that a more integrated healthcare system could enable pharmacists to provide effective and more efficient care to patients, the PDA proposed a model where at least two pharmacists would be working in each community pharmacy, empowered, and enabled with two-way referral pathways, having more clinical input and full access to patient records. "Such an environment could not only help to improve communications between health professionals and increase access to services for patients, but would support the NHS to operate more effectively."